A cheap and widely used steroid called dexamethasone has become the first drug shown to be able to save lives among COVID-19 patients in what scientists said is a “major breakthrough” in the coronavirus pandemic.
Novo Nordisk is expanding the company’s presence in treating kidney disease with the acquisition of U.S.-based Corvidia Therapeutics for $2.1 billion.
U.K.-based NodThera is building up the company’s war chest to develop therapies for diseases driven by chronic inflammation, securing $55 million in Series B financing.
The U.S. Food and Drug Administration approved a supplemental Biologics License Application for Eli Lilly and Company’s Taltz (ixekizumab) injection 80 mg/mL for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) in patients with objective signs of inflammation.
Geneius Biotechnology is developing T cells as a quasi-personalized, off-the-shelf, therapy and preventive measure against COVID-19.
Vancouver, Washington-based CytoDyn filed a second clinical trial protocol with the U.S. Food and Drug Administration to treat severely sick COVID-19 patients.
Atomwise, a leader in using artificial intelligence for small-molecule discovery, and Bridge Biotherapeutics, a clinical-stage biotech company, announced a research collaboration to launch up to 13 small-molecule programs across multiple therapeutic areas using structure-based AI technology for drug discovery.
Shares of Durect Corporation plunged more than 31 percent after the company announced the Phase IIa plaque psoriasis treatment sulfated oxysterol failed to distinguish itself against placebo.
Pharma giant Amgen became the most recent tenant of the Bay Area’s massive life sciences campus known as Gateway of the Pacific, with a 240,000-square-foot facility.
ChemoCentryx and VFMCRP announced that the companies’ pivotal Phase III ADVOCATE clinical trial of avacopan for ANCA-associated vasculitis hit the study’s primary endpoints.
